CIAM
BIO icon

Caitong International Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Caitong International Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-117
Closed -$35.5K – 2625
2025
Q4 		$35.5K Buy
117
+35
+43% +$10.9K 0.01% 832
2025
Q3 		$23K Sell
82
-30
-27% -$8.16K 0.02% 636
2025
Q2 		$27K Buy
112
+109
+3,633% +$25.8K 0.02% 423
2025
Q1 		$731 Buy
+3
New +$902 ﹤0.01% 1662

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Caitong International Asset Management's BIO Position: Q1 2026 in Review

Caitong International Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 117 shares — an estimated $35.5K sold.

Caitong International Asset Management first reported a position in BIO in Q1 2025 and held it in 4 quarters. The position peaked at $35.5K in Q4 2025. 392 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Caitong International Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Caitong International Asset Management sold 117 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $35.5K.
  • Caitong International Asset Management first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 4 quarters.
  • Caitong International Asset Management's Bio-Rad Laboratories Class A position peaked at $35.5K in Q4 2025.
  • 392 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.